Fractyl Health Appoints Zumdahl to Build Revita® Reimbursement Ahead of Q4 2026 Readout
GUTS•Fractyl Health has appointed Mike Zumdahl as SVP of Market Access and Commercial Strategy to build reimbursement and health economic infrastructure for its Revita® device ahead of REMAIN-1 pivotal cohort topline data expected in early Q4 2026. He previously led market access at Inari Medical through its $4.9 billion Stryker acquisition.
1. Appointment Details
Fractyl Health has named Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy, entrusting him with establishing reimbursement pathways and health economic models for the Revita® endoscopic procedure.
2. Strategic Rationale
With nearly one million U.S. patients discontinuing GLP-1 therapies each month, Fractyl aims to offer a durable weight-maintenance solution by ensuring robust payer coverage and economic value for Revita.
3. Zumdahl’s Track Record
Zumdahl brings extensive experience from Inari Medical, where he built global market access through its $4.9 billion Stryker acquisition, and from Novo Nordisk, where he contributed to GLP-1 category launches.
4. Development Timeline
Fractyl expects topline results from the REMAIN-1 pivotal cohort in early Q4 2026 and plans to submit a De Novo marketing application for Revita in late Q4 2026.
